Although the overexpression of EGFR and its ligands is prevalent in HNSCC patients and correlates with tumorigenesis, EGFR inhibitors that are either FDA‐approved or under investigation showed limited efficacy as monotherapies [8, 9, 14, 16]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.